Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.89M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.17M

Average 0.22M

NYXH Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Nyxoah S.A.NASDAQ: NYXH

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 30.2%

Gross margin was 30.2% in Q1 FY2026, down 31.7 pp from a year earlier. On a trailing-twelve-month basis it was 48.3%, down 17.2 pp year over year. Over 3 fiscal years it widened by 0.4 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
30.2%-34.1 pp QoQ
Last fiscal yearDec 2025
63.1%-2.5 pp YoY
LTMMar 2026
48.3%-17.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-31.7 pp——
1 year-2.5 pp——
3 years+0.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
63.1%
Year-over-year change
-2.5pp

Gross Margin vs competitors

How NYXH compares with its peers on the latest reported figures

  • NYXH's LTM Mar 2026 gross margin of 48.3% is the 5th highest of the 9 companies compared; the peer median is 50.8%.
  • Its year-over-year change of -17.2 pp is the 7th highest of 9, against a peer median of -2.0 pp.
  • Over three fiscal years its change of +0.4 pp compares with a peer median of -10.0 pp.
NYXH Competitors Peer median
Gross Margin for NYXH and competitors
Company Period LTM level YoY 3-year change
IVVDInvivyd, Inc.LTM Mar 202692.0% -1.3 pp—
KRMDKORU Medical Systems, Inc.LTM Mar 202661.5% -2.0 pp+7.2 pp
PREPrenetics Global LimitedLTM Mar 202658.3% +12.7 pp+25.3 pp
UTMDUtah Medical Products, Inc.LTM Mar 202653.6% -2.1 pp-10.0 pp
NYXHNyxoah S.A.LTM Mar 202648.3% -17.2 pp+0.4 pp
STIMNeuronetics, Inc.LTM Mar 202648.0% -15.6 pp-27.8 pp
OSUROraSure Technologies, Inc.LTM Mar 202641.0% -1.5 pp+3.6 pp
OABIOmniAb, Inc.LTM Mar 202635.5% -64.5 pp-118.2 pp
CATXPerspective Therapeutics, Inc.LTM Mar 2026-489.8% -407.5 pp-290.8 pp
TARAProtara Therapeutics, Inc.FY2025— ——
Peer median (excluding NYXH) 50.8%-2.0 pp-10.0 pp

Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue852K3.08M4.35M4.52M10.02M
Cost of Revenue303K1.15M1.66M1.55M3.69M
Gross Profit549K1.93M2.69M2.97M6.33M
Gross Margin64.4%62.7%61.9%65.7%63.1%
Research & Development5.95M15.86M27.66M34.33M42.82M
Selling, General & Admin11.11M18.86M20.65M28.46M46.44M
Operating Expenses26.79M34.43M47.79M61.78M89.27M
Depreciation & Amortization1.66M1.93M2.36M764K4.48M
EBITDA(22.59M)(27.89M)(42.08M)(53.77M)(82.9M)
EBITDA Margin-2651.5%-904.2%-967.8%-1189.2%-827.4%
Operating Income(26.24M)(32.5M)(45.1M)(58.81M)(82.94M)
Operating Margin-3080.0%-1053.8%-1037.3%-1300.8%-827.8%
Interest Income1K372K2.57M2.5M1.83M
Interest Expense386K237K1.21M1.9M1.69M
Other Income / Expenses1.6M2.44M445K2.38M(6.13M)
Income Before Tax(24.64M)(30.06M)(44.66M)(56.43M)(89.08M)
Pre-Tax Margin-2891.9%-974.6%-1027.1%-1248.2%-889.0%
Income Tax Expense2.98M1.17M(1.45M)2.8M1.01M
Net Income(27.62M)(31.23M)(43.21M)(59.24M)(90.09M)
Net Margin-3241.7%-1012.5%-993.8%-1310.2%-899.1%
EPS (Basic)(1.16)(1.21)(1.55)(1.81)(2.37)
EPS (Diluted)(1.16)(1.21)(1.55)(1.81)(2.37)
Weighted Avg Shares23.79M25.82M27.97M32.74M38.11M
Weighted Avg Shares (Diluted)23.79M25.82M27.97M32.74M38.11M

Nyxoah S.A.

NASDAQ:NYXH

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.